• CLOUDBREAK PHARMA Announces 2025 Annual Results

    Key Clinical Trials Progress Steadily Continuously Building an Integrated Commercial System【Hong Kong, 13 April, 2026】CLOUDBREAK PHARMA INC. (“CLOUDBREAK PHARMA” or the “Company”; Stock Code: 25... (全文)
    2026-04-14
  • Joyson Electronics posts FY2025 revenue of RMB 61.2 bln; pro...2026-04-080
  • Haitian Flavouring Releases 2025 Annual Results: Multi-Dimen...2026-04-030
  • ManpowerGroup Greater China Announces 2025 Annual Results2026-03-310
  • CMGE Announces 2025 Annual Results Loss Narrowed Significan...2026-03-300
  • Haitian Flavouring Releases 2025 Annual Results: Multi-Dimen...2026-03-301
  • HKIRA 12th IR Awards 2026 now open for nomination Innovatio...2026-02-056
  • Beisen Releases First ESG Value Accounting Report in Global ...2026-01-291
  • Haitian Flavoring goes public! A+H dual platform debuts, con...2025-06-260
  • Haitian Flavoring reports 2024 double-digit profit growth as...2025-04-091
Phillip Securities (HK) Limited has taken measures to ensure the information provided herein is accurate and reliable, but we do not guarantee the completeness and truthfulness of these information, and are not responsible for any errors or omissions relating to the information provided by third parties.Copyright 2022 Phillip Securities Group. All Rights Reserved.